Need for increased dose of warfarin in HIV patients taking nevirapine

Dionisio, Daniele; Mininni, Simone; Bartolozzi, Dario; Esperti, Francesco; Vivarelli, Angela; Leoncini, F

doi:10.1097/00002030-200101260-00021

Cited by 30 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the many classes of antiretrovirals, the majority of the interactions are seen with the non-nucleotide reverse-transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) [56][57][58], as both are metabolized by multiple CYP450 enzymes. The NNRTI, nevirapine is a substrate and a selective inducer of CYP3A4 and CYP2B6 [59,60]. Four case reports have documented an induction interaction in which the patient required an increased dose of warfarin to maintain a therapeutic INR [57,59].…”

Section: Anti-infective Agentsmentioning

confidence: 99%

“…The NNRTI, nevirapine is a substrate and a selective inducer of CYP3A4 and CYP2B6 [59,60]. Four case reports have documented an induction interaction in which the patient required an increased dose of warfarin to maintain a therapeutic INR [57,59]. Efavirenz has both inhibition and induction effects on CYP3A4.…”

Section: Anti-infective Agentsmentioning

confidence: 99%

“…Etravirine is a second generation NNRTI, a potent inhibitor of CYP2C9 and CYP2C19, and is both an inhibitor and inducer of CYP3A4 [60]. Nine cases have been reported involving drug interactions with PIs and warfarin due to the high affinity of PIs for CYP3A4 [59,[61][62][63][64][65][66]. Of the documented case reports, ritonavir is cited most often as a potent inhibitor of this CYP isoform.…”

Section: Anti-infective Agentsmentioning

confidence: 99%

See 2 more Smart Citations

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

Nutescu

Chuatrisorn

Hellenbart

2011

J Thromb Thrombolysis

222

153

View full text Add to dashboard Cite

Clinicians and patients around the world have been intrigued by the concept of developing an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions that can be administered at fixed doses with no or minimal monitoring. The recently approved oral direct thrombin inhibitor dabigatran, along with the emerging oral anti-factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have been developed to address many of the shortcomings of warfarin therapy. As warfarin is associated with extensive food and drug interactions, there is also a need to consider such interactions with the new oral anticoagulants. While to date few drug and dietary interactions have been reported with the new oral anticoagulants, it is still early in their development and clinical use cycle. Pharmacokinetic and pharmacodynamic profiles will have to be closely accounted for when determining the likelihood of a potential drug interaction prior to therapy initiation. As the list of drugs and supplements that interact with warfarin is continuously expanding, and the knowledge on drug interactions with the novel oral anticoagulants is still in its infancy, clinicians need to be vigilant when initiating any of these agents or when any changes in the patient's medication profile occur and perform a close screening for potential drug and dietary interactions. The objective of this paper is to give an update on drug and dietary interactions with warfarin and the novel oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban.

show abstract

Section: Anti-infective Agentsmentioning

confidence: 99%

Section: Anti-infective Agentsmentioning

confidence: 99%

Section: Anti-infective Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

Nutescu

Chuatrisorn

Hellenbart

2011

J Thromb Thrombolysis

222

153

View full text Add to dashboard Cite

show abstract

“…3 We identified 76 patients with severe PJP, including 25 (33%) before and 51 during the highly active antiretroviral therapy (HAART) era; only nine (9/51; 18%) were taking HAART at the diagnosis of severe PJP. Median age was 40 years, and 59 (59/76; 78%) patients were men.…”

Section: Favourable Use Of Non-boosted Fosamprenavir In Patients Treamentioning

confidence: 99%

Favourable use of non-boosted fosamprenavir in patients treated with warfarin

et al. 2009

View full text Add to dashboard Cite

2 Cavalcanti AL, Bagnoli VR, Fonseca AM, et al. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115-9 3 Laan E, van Driel EM, van Lunsen RH. Genital responsiveness in healthy women with and without sexual arousal disorder. J Sex Med 2008;5:1424-35 4 Suschinsky KD, Lalumiere ML, Chivers ML. Sex differences in patterns of genital sexual arousal: measurement artefacts or true phenomena? Arch Sex Behav 2008; (epub ahead of print) 5 Chivers ML, Rieger G, Latty E, Bailey JM. A sex difference in the specificity of sexual arousal. Psychol Sci 2004;15:736 -44 6 Rellini AH, McCall KM, Randall PK, Meston CM. The relationship between women's subjective and physiological sexual arousal. Psychophysiology 2005;42:116-24

show abstract

“…Women who display greater orgasmic consistency from penile -vaginal intercourse show greater concordance of genital (vaginal pulse amplitude) and subjective sexual arousal than women who do not orgasm from penile -vaginal intercourse (regardless of their orgasmic consistency during other sexual activities, alone or with a partner). 2,3 Foster et al 1 also noted that in their own clinical series, PDE5i response appeared to be more common in women with 'stable and/or happy relationships' ( p. 156). Non-response appeared to be more common in the 'presence of psychological co-morbidities' ( p. 156).…”

mentioning

confidence: 92%